Genetics of Mast Cell Activation (MCAS)
Mast Cell Activation Syndrome (MCAS) involves inappropriate or excessive activation of mast cells, releasing histamine and other mediators. MCAS overlaps significantly with Long COVID, ME/CFS, and connective tissue disorders, and has both genetic and immune-mediated contributors.
This page is for educational and informational purposes only. Not a diagnostic tool. Always consult a qualified healthcare provider.
What is Mast Cell Activation (MCAS)?
Mast cells are tissue-resident immune cells that release a wide array of inflammatory mediators — including histamine, tryptase, prostaglandins, and cytokines — upon activation. In MCAS, mast cells activate inappropriately or excessively, producing multisystem symptoms including urticaria, flushing, gastrointestinal distress, cardiovascular instability, and anaphylaxis-like reactions. Genetic variants in mast cell signalling receptors (KIT, FcεRI), histamine metabolism genes (HNMT, DAO), and inflammatory mediator pathways may influence mast cell activation thresholds and mediator release patterns.
Biological pathways commonly discussed in relation to Mast Cell Activation (MCAS)
Research into Mast Cell Activation Syndrome has highlighted several biological pathways that may be relevant. Genetic variants within these pathways may influence individual susceptibility, symptom severity, or the trajectory of the condition.
Mast Cell Signalling
The KIT receptor (encoded by KIT/CD117) and IgE receptor (FcεRI, encoded by FCER1A) are primary mast cell activation pathways. Variants affecting their signalling thresholds may alter mast cell reactivity.
Histamine Metabolism
Histamine is released during mast cell activation and broken down by HNMT (intracellular) and DAO (extracellular). Variants reducing these enzymes may increase histamine exposure and sensitivity.
Ige Mediated Activation
IgE antibodies bound to mast cell FcεRI receptors trigger degranulation upon antigen crosslinking. Genetic variants in IgE production, Fc receptor affinity, and mast cell sensitisation thresholds may influence allergic and MCAS responses.
Mast Cell Mediators
Mast cells release over 200 mediators including tryptase, prostaglandins (PGD2), leukotrienes (LTC4), and cytokines (TNF, IL-4). Variants in biosynthesis enzymes (TPSAB1, PTGS1, ALOX5) may influence mediator profiles.
Key genes studied in relation to Mast Cell Activation (MCAS)
The following genes have been studied in relation to Mast Cell Activation Syndrome. These genes span the biological pathways most commonly discussed in this area of research.
17 genes total studied in relation to Mast Cell Activation (MCAS) across the ChronicDNA dataset.
Genetic variants commonly discussed
The following genetic variants (SNPs) are found in genes that have been studied in relation to Mast Cell Activation (MCAS). Each variant represents a position in the genome where individuals may carry different alleles.
46 variants total across genes studied in relation to Mast Cell Activation (MCAS).
How personal DNA data may provide educational insights
Consumer DNA files from 23andMe, AncestryDNA, and MyHeritage contain raw SNP data. When you upload your file to ChronicDNA, the analysis engine checks your genotype against a curated panel of 80+ genes selected for their relevance to Long COVID, ME/CFS, and connected biological pathways - some of which may relate to areas such as Mast Cell Activation (MCAS).
This is not a diagnostic service. Genetic variants do not determine whether you have Mast Cell Activation (MCAS), nor do they predict your clinical outcomes. The report is educational - it explains which variants you carry, what the research says about them, and how they fit into the biological pathways most relevant to chronic illness. All results should be discussed with a qualified healthcare provider.
Related conditions and pathways
Mast Cell Activation (MCAS) shares biological pathways and genetic associations with the following related conditions and areas of research.
Frequently asked questions
What is MCAS and how is it related to Long COVID?
MCAS involves inappropriate mast cell activation causing multisystem symptoms. It is significantly over-represented in Long COVID patients, where mast cell activation may be triggered or amplified by viral infection, immune dysregulation, or autoantibodies against mast cell receptors.
Which genes are studied in relation to MCAS?
Key genes include KIT, FCER1A, TPSAB1, HNMT, DAO, PTGS1, ALOX5, and MS4A2. These cover mast cell signalling, histamine metabolism, tryptase expression, and inflammatory mediator synthesis.
What is histamine intolerance and how does it relate to MCAS?
Histamine intolerance involves symptoms triggered by histamine-rich foods or excessive histamine release, often due to reduced DAO or HNMT enzyme activity. It overlaps with but is distinct from MCAS — both may involve impaired histamine metabolism, but MCAS involves aberrant mast cell activation beyond just histamine.
Is MCAS hereditary?
Primary mast cell disorders (such as mastocytosis with KIT D816V mutation) have a genetic component. MCAS is more heterogeneous — while variants in mast cell signalling and histamine metabolism genes may predispose, environmental and immune triggers are often also involved.
Related articles
- Long COVID MCAS: Mast Cells, Histamine and Your Genes
Learn how Long COVID MCAS may develop, how it overlaps with POTS and histamine intolerance, and which genes research links to mast cell activity.
Explore DNA insights
If you already have DNA data from 23andMe, AncestryDNA, or MyHeritage, upload your raw file to ChronicDNA and receive a personalised educational report covering genes studied in relation to Mast Cell Activation (MCAS) and connected biological pathways.
Get Your Personalised DNA ReportInformational and educational only · Not a diagnostic tool · GDPR compliant
17 genes · 46 variants analysed in relation to Mast Cell Activation (MCAS)